Vaxart initiates Phase 1 trial for oral norovirus vaccine; topline data expected mid-2025

Vaxart, Inc.

Phase 1 open-label dose-ranging trial evaluating second-generation oral norovirus pill vaccine vs first-generation constructs.
Topline data expected as early as mid-2025.
If successful, Phase 2 could start H2 2025, Phase 3 as early as 2026, subject to partnership or other funding.
No vaccines currently approved for norovirus; Vaxart's oral pill is the only clinical-stage candidate.
CEO Steven Lo cites urgent public health need as norovirus spreads globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.